Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, as demonstrated by clinical, virologic, and radiologic response to treatment. However, the treatment also resulted in immune reconstitution inflammatory syndrome and lif...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambert, Nicolas, Dauby, Solène, Dive, Dominique, Sadzot, Bernard, Maquet, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714204/
https://www.ncbi.nlm.nih.gov/pubmed/34856110
http://dx.doi.org/10.3201/eid2801.204809
_version_ 1784623870449287168
author Lambert, Nicolas
Dauby, Solène
Dive, Dominique
Sadzot, Bernard
Maquet, Pierre
author_facet Lambert, Nicolas
Dauby, Solène
Dive, Dominique
Sadzot, Bernard
Maquet, Pierre
author_sort Lambert, Nicolas
collection PubMed
description Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, as demonstrated by clinical, virologic, and radiologic response to treatment. However, the treatment also resulted in immune reconstitution inflammatory syndrome and life-threatening immune-related adverse events. These conditions were treated with corticosteroids, leading to treatment resistance.
format Online
Article
Text
id pubmed-8714204
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-87142042022-01-04 Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy Lambert, Nicolas Dauby, Solène Dive, Dominique Sadzot, Bernard Maquet, Pierre Emerg Infect Dis Research Letter Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, as demonstrated by clinical, virologic, and radiologic response to treatment. However, the treatment also resulted in immune reconstitution inflammatory syndrome and life-threatening immune-related adverse events. These conditions were treated with corticosteroids, leading to treatment resistance. Centers for Disease Control and Prevention 2022-01 /pmc/articles/PMC8714204/ /pubmed/34856110 http://dx.doi.org/10.3201/eid2801.204809 Text en https://creativecommons.org/licenses/by/4.0/Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research Letter
Lambert, Nicolas
Dauby, Solène
Dive, Dominique
Sadzot, Bernard
Maquet, Pierre
Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
title Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
title_full Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
title_fullStr Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
title_full_unstemmed Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
title_short Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
title_sort atezolizumab treatment for progressive multifocal leukoencephalopathy
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714204/
https://www.ncbi.nlm.nih.gov/pubmed/34856110
http://dx.doi.org/10.3201/eid2801.204809
work_keys_str_mv AT lambertnicolas atezolizumabtreatmentforprogressivemultifocalleukoencephalopathy
AT daubysolene atezolizumabtreatmentforprogressivemultifocalleukoencephalopathy
AT divedominique atezolizumabtreatmentforprogressivemultifocalleukoencephalopathy
AT sadzotbernard atezolizumabtreatmentforprogressivemultifocalleukoencephalopathy
AT maquetpierre atezolizumabtreatmentforprogressivemultifocalleukoencephalopathy

Ejemplares similares